marked.bio

Company

Zhejiang Anglikang Pharmaceutical

2 active trials that select patients by a biomarker on marked.bio, across 2 biomarkers.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Trials

2 of 2 trials shown

  1. A Phase Ib/II Study Evaluating Injectable ALK-N001 in Patients With Advanced Solid Tumors

    Not yet recruiting Phase 1/2 Zhejiang Anglikang Pharmaceutical Started 2026Primary completion 2027-12 NCT07509684

    ALK-N001 for Injection

    … cancer, esophageal cancer, liver cancer, breast cancer (triple-negative breast cancer or HER2 low/ultra-low expression breast cancer), ovarian cancer, cervical cancer, and other tumor typ…

    HER2-low / ultralow (IHC 1+ or 2+/ISH-)Advanced Solid Tumors

  2. A Phase IIa Study Evaluating Injectable ALK-N001 in Patients With Advanced Gastrointestinal Tumors

    Not yet recruiting Phase 2 Zhejiang Anglikang Pharmaceutical Started 2026Primary completion 2027-12 NCT07826195

    Injectable ALK-N001

    For MSI-H/dMMR tumors, prior PD-(L)1 inhibitor is required.

    MSI-H / dMMRAdvanced Gastrointestinal Tumors